Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Sep 1;106-B(9):924-934.
doi: 10.1302/0301-620X.106B9.BJJ-2023-1252.R2.

Efficacy and safety of commonly used thromboprophylaxis agents following hip and knee arthroplasty

Tim Cheok  1   2   3 , Alexander Beveridge  2   4 , Morgan Berman  5 , Martin Coia  2 , Alexander Campbell  6 , Tycus T S Tse  2 , Job N Doornberg  3   7   8 , Ruurd L Jaarsma  3   7
Affiliations

Efficacy and safety of commonly used thromboprophylaxis agents following hip and knee arthroplasty

Tim Cheok et al. Bone Joint J. .

Abstract

Aims: We investigated the efficacy and safety profile of commonly used venous thromboembolism (VTE) prophylaxis agents following hip and knee arthroplasty.

Methods: A systematic search of PubMed, Embase, Cochrane Library, Web of Science, and OrthoSearch was performed. Prophylaxis agents investigated were aspirin (< 325 mg and ≥ 325 mg daily), enoxaparin, dalteparin, fondaparinux, unfractionated heparin, warfarin, rivaroxaban, apixaban, and dabigatran. The primary efficacy outcome of interest was the risk of VTE, whereas the primary safety outcomes of interest were the risk of major bleeding events (MBE) and wound complications (WC). VTE was defined as the confirmed diagnosis of any deep vein thrombosis and/or pulmonary embolism. Network meta-analysis combining direct and indirect evidence was performed. Cluster rank analysis using the surface under cumulative ranking (SUCRA) was applied to compare each intervention group, weighing safety and efficacy outcomes.

Results: Of 86 studies eligible studies, cluster rank analysis showed that aspirin < 325 mg daily (SUCRA-VTE 89.3%; SUCRA-MBE 75.3%; SUCRA-WC 71.1%), enoxaparin (SUCRA-VTE 55.7%; SUCRA-MBE 49.8%; SUCRA-WC 45.2%), and dabigatran (SUCRA-VTE 44.9%; SUCRA-MBE 52.0%; SUCRA-WC 41.9%) have an overall satisfactory efficacy and safety profile.

Conclusion: We recommend the use of either aspirin < 325 mg daily, enoxaparin, or dabigatran for VTE prophylaxis following hip and knee arthroplasty.

PubMed Disclaimer

Conflict of interest statement

None declared.

References

    1. Wendelboe AM , Raskob GE . Global burden of thrombosis . Circ Res . 2016 ; 118 ( 9 ): 1340 – 1347 . 10.1161/CIRCRESAHA.115.306841 27126645
    1. Bell EJ , Lutsey PL , Basu S , et al. Lifetime risk of venous thromboembolism in two cohort studies . Am J Med . 2016 ; 129 ( 3 ): 339 . 10.1016/j.amjmed.2015.10.014 26597668
    1. Warwick DJ , Whitehouse S . Symptomatic venous thromboembolism after total knee replacement . J Bone Joint Surg Br . 1997 ; 79-B ( 5 ): 780 – 786 . 10.1302/0301-620x.79b5.7761 9331035
    1. McNally MA , Mollan RA . Total hip replacement, lower limb blood flow and venous thrombogenesis . J Bone Joint Surg Br . 1993 ; 75-B ( 4 ): 640 – 644 . 10.1302/0301-620X.75B4.8331123 8331123
    1. McNally MA , Bahadur R , Cooke EA , Mollan RAB . Venous haemodynamics in both legs after total knee replacement . J Bone Joint Surg Br . 1997 ; 79-B ( 4 ): 633 – 637 . 10.1302/0301-620X.79B4.0790633 9250754

Publication types

MeSH terms